Skip to content

US · NXTC · BIOTECHNOLOGY

NextCure, Inc. (NXTC) intrinsic value and stock valuation

$6.45as of 2026-11-21 · Mkt cap 18.96M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NextCure, Inc. DCF and intrinsic value

InvestorsCraft values NXTC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NXTC’s statements →

NextCure, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Beltsville, MD 20705 nextcure.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-55.84M
20172025
Free cash flow
-$-49.61M
20172025
Total equity
$34.9M-34.7% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-57.62M-$-59.75M-$-67.64M-$-75.91M-$-70.77M
Net income-$-55.84M-$-55.65M-$-62.72M-$-74.73M-$-69.39M
EPSd-$-19.66M-$-23.88M-$-27.03M-$-32.35M-$-30.17M
Operating cash flow-$-49.61M-$-40.8M-$-52.97M-$-53.89M-$-57.24M
Capital expenditure$0.00-$-470K-$-820K-$-2.12M-$-2.36M
Free cash flow-$-49.61M-$-41.28M-$-53.79M-$-56M-$-59.6M
Total assets$50.2M$80.9M$128M$184.2M$242.4M
Total debt$5.15M$5.95M$6.61M$7.12M$0.00
Net debt-$-20.83M-$-21.78M-$-6.48M-$-19.51M-$-12.34M
Total equity$34.9M$65.5M$114.4M$167.5M$233.4M
Cash and short-term investments$41.8M$68.6M$108.3M$159.9M$219.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$2.19M$0.00$0.00$0.00$0.00
Gross profit-$-2.19M$0.00$0.00$0.00$0.00
Research and development expenses$44.9M$41.5M$47.9M$54.2M$50.2M
Selling, general and administrative expenses$12.7M$15.7M$19.7M$21.7M$20.6M
Other expenses-$-2.19M$2.54M$0.00$0.00$0.00
Operating expenses$55.4M$59.8M$67.6M$75.9M$70.8M
Cost and expenses$57.6M$59.8M$67.6M$75.9M$70.8M
Interest income$0.00$0.00$0.00$1.17M$0.00
Interest expense$0.00$0.00$0.00$0.00$80K
Depreciation and amortization$2.19M$2.87M$3.68M$4.12M$4.18M
Ebitda-$-53.66M-$-54.34M-$-59.04M-$-70.61M-$-65.14M
Operating income-$-57.62M-$-59.75M-$-67.64M-$-75.91M-$-70.77M
Total other income/expenses, net$1.77M$4.09M$4.91M$1.18M$1.38M
Income before tax-$-55.84M-$-55.65M-$-62.72M-$-74.73M-$-69.39M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-55.84M-$-55.65M-$-62.72M-$-74.73M-$-69.39M
Weighted average shares outstanding$2.84M$2.33M$2.32M$2.31M$2.3M
Weighted average diluted shares outstanding$2.84M$2.33M$2.32M$2.31M$2.3M
Balance sheet
20252024202320222021
Cash and short-term investments$41.8M$68.6M$108.3M$159.9M$219.6M
Net receivables$100K$300K$800K$700K$0.00
Inventory$0.00$0.00$0.00-$-700K$0.00
Total current assets$43.8M$71.8M$112.7M$164M$227.8M
Property, plant and equipment, net$5.89M$8.72M$13.4M$16.9M$14M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$6.44M$9.05M$15.3M$20.2M$14.6M
Total assets$50.2M$80.9M$128M$184.2M$242.4M
Accounts payable$2.01M$5.35M$2.33M$4.27M$1.94M
Short-term debt$1M$800K$660K$520K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$10.6M$9.57M$6.88M$9.13M$6.61M
Long-term debt$4.15M$5.15M$5.95M$6.61M$0.00
Deferred revenue, non-current$0.00$0.00$0.00-$-1.54M$0.00
Total non-current liabilities$4.67M$5.81M$6.73M$7.5M$2.39M
Capital lease obligations$1M$5.95M$6.61M$7.12M$0.00
Total liabilities$15.2M$15.4M$13.6M$16.6M$9M
Common stock$0.00$30K$30K$30K$30K
Retained earnings-$-435.98M-$-380.14M-$-324.48M-$-261.76M-$-187.03M
Accumulated other comprehensive income (loss)$20K$0.00-$-220K-$-1.49M-$-660K
Total equity$34.9M$65.5M$114.4M$167.5M$233.4M
Total investments$15.8M$40.9M$95.2M$133.3M$207.3M
Total debt$5.15M$5.95M$6.61M$7.12M$0.00
Net debt-$-20.83M-$-21.78M-$-6.48M-$-19.51M-$-12.34M
Cash flow statement
20252024202320222021
Net income-$-55.84M-$-55.65M-$-62.72M-$-74.73M-$-69.39M
Depreciation and amortization$1.7M$2.87M$3.68M$4.12M$7.2M
Stock-based compensation$2.99M$6.33M$8.19M$9.51M$10.3M
Change in working capital$950K$4.53M-$-1.94M$3.73M-$-5.34M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-3.34M$3.02M-$-1.94M$2.33M-$-1.96M
Net cash provided by operating activities-$-49.61M-$-40.8M-$-52.97M-$-53.89M-$-57.24M
Investments in property, plant and equipment$0.00-$-470K-$-820K-$-2.12M-$-2.36M
Acquisitions, net$0.00$0.00$0.00-$-70K-$-40K
Net cash used for investing activities$25.6M$55.3M$39.3M$68M$36.6M
Common stock issued$22.3M$40K$150K$200K$210K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$22.3M$140K$150K$200K-$-3.27M
Net change in cash-$-1.75M$14.6M-$-13.55M$14.3M-$-23.91M
Cash at end of period$26M$27.7M$13.1M$26.6M$12.4M
Operating cash flow-$-49.61M-$-40.8M-$-52.97M-$-53.89M-$-57.24M
Capital expenditure$0.00-$-470K-$-820K-$-2.12M-$-2.36M
Free cash flow-$-49.61M-$-41.28M-$-53.79M-$-56M-$-59.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NextCure, Inc.

        NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.

        CEO
        Michael S. Richman
        Employees
        40
        Beta
        1.27

        Explore

        Frequently asked questions

        What is the intrinsic value of NextCure, Inc. (NXTC)?

        InvestorsCraft does not currently publish an intrinsic value for NXTC. How the IC value is calculated.

        Is NXTC undervalued?

        InvestorsCraft does not publish an undervaluation signal for NXTC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.